Monoamine Oxidase B inhibitor 1 

Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 0.02 nM. Monoamine Oxidase B inhibitor 1 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 1 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study^[1].

In cellular experiments, Monoamine Oxidase B inhibitor 1 (compound 14a; 0.5-10.0 μM) could significantly decrease the production of NO and TNF-α in LPS-stimulated BV-2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In in vivo acute and subacute MPTP-induced mice model of Parkinson’s disease, Monoamine Oxidase B inhibitor 1 (compound 14a; 6-37.4 mg/kg; oral administration) could significantly improve most behavioral disorders, restore the dopamine content and decrease the MDA content in the mice striatum^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

298.31

C₁₈H₁₅FO₃

2807477-70-7

C=CCC1OC(C2=CC(OCC3=CC=C(C=C3)F)=CC=C21)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Qing Song, et al. 6-Benzyloxyphthalides as selective and reversible monoamine oxidase B inhibitors with antioxidant and anti-neuroinflammatory activities for Parkinson's disease treatment. Bioorg Chem. 2022 Mar;120:105623.  [Content Brief]